Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)

International Journal of Antimicrobial Agents

Volumn 24, Issue 2, 2004, Pages 111-118

  Streit, Jennifer M ^a   Jones, Ronald N ^a,b   Sader, Helio S ^a   Fritsche, Thomas R ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial susceptibility; Intensive care unit; SENTRY; Surveillance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM DERIVATIVE; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DALFOPRISTIN; GENTAMICIN; GLYCOPEPTIDE; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; SULFAMETHOXAZOLE; TAZOBACTAM; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; LABORATORY TEST; NORTH AMERICA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; STAPHYLOCOCCUS AUREUS; URINE; WOUND;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; POPULATION SURVEILLANCE;

EID: 3342962524     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.12.019     Document Type: Article

References (36)

1. Archibald L., Phillips L., Monnett D., McGowan J.E. Jr., Tenover F. Jr., Gaynes R. Antimicrobial resistance in hospitals and outpatients in the United States: the increasing importance of the intensive care unit. Clin Infect. Dis. 24:1997;211-215
2. Fridkin S.K., Hill H.A., Volkova N.V., et al. The Intensive Care Antimicrobial Resistance Epidemiology (CARE) Project Hospitals. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. Emerg Infect. Dis. 8:2002;697-701
3. Fridkin S.K., Gaynes R.P. Antimicrobial resistance in intensive care units. Clin Chest Med. 20:1999;303-316
4. Heyland D.K., Cook D.J., Griffith L., Keenan S.P., Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am. J. Respir. Crit. Care Med. 159:1999;1249-1256
5. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk-factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 274:1995;968-974
6. Schales D.M., Gerding D.N., John J.F., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance Guidelines for the prevention of antimicrobial resistance in hospitals. Infect. Control Hosp. Epidemiol. 18:1997;275-291
7. Vincent J.L., Bihari D.J., Suter P.M., et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. Epic International Advisory Committee. JAMA. 274:1995;639-644
8. Itokazu G.S., Quinn J.P., Bell-Dixon C., Kahan F.M., Weinstein R.A. Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect. Dis. 23:1996;779-784
9. Spencer R.C. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;281-285
10. Edgeworth J.D., Treacher D.F., Eykyn S.J. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit. Care Med. 27:1999;1421-1428
11. Garcia-Rodriguez J.-A., Jones R.N. The MYSTIC Programme Study Group Antimicrobial resistance in Gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. J. Chemother. 14:2002;25-32
12. Pfaller M.A., Jones R.N., Doern G.V., Kugler K. The SENTRY Participants Group Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42:1998;1762-1770
13. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin. Respr. Crit. Care Med. 24:2003;121-133
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial tests for bacteria that grows aerobically. Approved standard M7-A6. Wayne, PA:NCCLS; 2003.
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S13. Wayne, PA:NCCLS; 2003.
16. Tenover F.C., Arbeit R.D., Goering R.V., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin Microbiol. 33:1995;2233-2239
17. Fridkin S.K., Steward C.D., Edwards J.R., et al. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals. Surveillance of antimicrobial use and antimicrobial resistance in US hospital: project ICARE Phase 2. Clin Infect. Dis. 29:1999;245-252
18. Aksaray S., Dokuzoguz B., Guvener E., et al. Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in eight hospitals in Turkey. J. Antimicrob. Chemother. 45:2000;695-699
19. Weinstein R. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect. Dis. 7:2001;188-191
20. Quale J., Landman D., Saurina G., Atwood E., DiTore V., Patel K. Manipulation of a hospital formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect. Dis. 23:1996;1020-1025
21. Gaynes R., Monnet D. The contribution of antibiotic use on the frequency of antibiotic resistance in hospitals. Ciba Found Symp. 207:1997;47-56
22. Landman D., Chockalingam M., Quale J.M. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect. Dis. 28:1999;1062-1066
23. Fridkin S.K., Edwards J.R., Courval J.M., et al. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 US adult intensive care units. Ann. Intern. Med. 135:2001;175-183
24. Fluit A.C., Verhoef J., Schmitz F.-J. The European SENTRY Participants Frequency of isolation and antimicrobial resistance of Gram-negative and Gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur. J. Clin Microbiol. Infect. Dis. 20:2001;617-625
25. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA. 289:2003;885-888
26. Goff D.A., Sierawski S.J. Clinical experience of quinupristin/ dalfopristin for the treatment of antimicrobial-resistant Gram-positive infections. Pharmacotherapy. 22:2002;748-758
27. Low D.E., Keller N., Barth A., Jones R.N. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl 2):2001;S133-S145
28. Clark N., Cooksey R., Hill B., Swenson J., Tenover F. Characterization of glycopeptide-resistant enterococci from US hospitals. Antimicrob Agents Chemother. 37:1993;2311-2317
29. Huycke M.M., Sahm D.F., GiImore M.S. Multiple drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg. Infect. Dis. 4:1998;239-249
30. Andrade S.S., Jones R.N., Gales A.C., Sader H.S. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J. Antimicrob. Chemother. 52:2003;140-141
31. Levin A.S., Barone A.A., Penco J., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect. Dis. 28:1999;1008-1011
32. Karas J. Treatment failure due to extended-spectrum β-lactamases. J. Antimicrob. Chemother. 37:1996;203-204
33. Patterson D.L., Ko W.C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Antimicrob. Chemother. 39:2001;2206-2212
34. Winokur P., Canton R. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect. Dis. 32:2001;94-103
35. McCormack J.G., Yu V. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Antimicrob. Chemother. 39:2001;2206-2212
36. Hanberger H., Diekema D., Fluit A., et al. Surveillance of antibiotic resistance in European ICUs. J. Hosp. Infect. 48:2001;161-176